Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.

about

Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.

Item

http://www.wikidata.org/entity/Q41156034

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Lenalidomide in patients with ...... entre "real-world" experience.

@en

type

Item

label

Lenalidomide in patients with ...... entre "real-world" experience.

@en

prefLabel

Lenalidomide in patients with ...... entre "real-world" experience.

@en

P1476

Lenalidomide in patients with ...... entre "real-world" experience.

@en

P2093

Alessandra Sottini

http://www.w3.org/2001/XMLSchema#string

Annamaria Pelizzari

http://www.w3.org/2001/XMLSchema#string

Chiara Pagani

http://www.w3.org/2001/XMLSchema#string

Cinzia Lamorgese

http://www.w3.org/2001/XMLSchema#string

Daniela Bellotti

http://www.w3.org/2001/XMLSchema#string

Elisa Cerqui

http://www.w3.org/2001/XMLSchema#string

Erika Borlenghi

http://www.w3.org/2001/XMLSchema#string

Francesca Schieppati

http://www.w3.org/2001/XMLSchema#string

Luisa Imberti

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.

Reporting results of cancer treatment

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.

Efficacy of lenalidomide in myelodysplastic syndromes.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

P304

3129-3134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1034703

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Leonardo Boiocchi

Giuseppe Rossi

P577

2015-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25811676

http://www.w3.org/2001/XMLSchema#string